ClinicalTrials.gg
CompletedNCT05428696Updated Jun 7, 2024

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

A Phase 1 interventional study of ALXN2080 and Placebo in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is designed to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ALXN2080 in healthy adult participants.

Read the detailed description

Participants will be assigned to 10 different cohorts (6 SAD cohorts and 4 MAD cohorts), each with 8 participants on active treatment with ALXN2080 and 2 participants on placebo. ALXN2080 will be administered under fasted conditions throughout this study, except for the last SAD Cohort 6 in which ALXN2080 will be given with food to evaluate the effect of food on the single-dose pharmacokinetics of ALXN2080.

02

Conditions studied

  • Healthy

Keywords

  • ALXN2080
  • Complement system
  • Pharmacokinetics
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy is defined as having no abnormalities identified by a detailed medical history, physical examination, blood pressure and heart rate measurements, 12-lead , and clinical laboratory tests.
  • (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg. BMI max is 32 kg/m2.
  • Male or female; female of and male participants agreed to follow protocol specified guidance.

Exclusion criteria

Exclusion Criteria:

  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders.
  • History of to any ingredient contained in the study intervention.
  • Evidence of active infections, history of meningococcal infection, unexplained, or recurrent infection.
  • Known or suspected history of drug or alcohol abuse or dependence.
  • Current tobacco users or smokers.
  • Diseases or conditions or previous procedures known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • For females: pregnant, breastfeeding, or intending to conceive during the course of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    SAD - Cohort 1

    Eight participants will receive a single dose of Dose Amount 1 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    SAD - Cohort 2

    Eight participants will receive a single dose of Dose Amount 2 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    SAD - Cohort 3

    Eight participants will receive a single dose of Dose Amount 3 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    SAD - Cohort 4

    Eight participants will receive a single dose of Dose Amount 4 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    SAD - Cohort 5

    Eight participants will receive a single dose of Dose Amount 5 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    SAD - Cohort 6

    Eight participants will receive a single dose of Dose Amount 6 of ALXN2080, and 2 participants will receive placebo.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    MAD - Cohort 1

    Eight participants will receive multiple doses of Dose Amount A of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    MAD - Cohort 2

    Eight participants will receive multiple doses of Dose Amount B of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    MAD - Cohort 3

    Eight participants will receive multiple doses of Dose Amount C of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.

    Drug: ALXN2080 · Drug: Placebo

  • Experimental
    MAD - Cohort 4

    Eight participants will receive multiple doses of Dose Amount D of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.

    Drug: ALXN2080 · Drug: Placebo

Interventions

  • Powder-in-capsule

  • DrugPlacebo

    Powder-in-capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 through up to Day 28

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) Of Single Dose ALXN2080

    Time frame: Up to 168 hours postdose

  2. Maximum Observed Plasma Concentration (Cmax) of Single Dose ALXN2080

    Time frame: Up to 168 hours postdose

07

Study locations

1 site
  • Clinical Trial Site
    Belfast, BT9 6AD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
Jun 23, 2022
StartActual
Sep 12, 2022
Primary completionActual
Apr 24, 2023
CompletionActual
May 26, 2023
Last update
Jun 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05428696
Collaborators
Celerion
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Sep 12, 2022
Primary completion
Apr 24, 2023
Completion
May 26, 2023
Last update
Jun 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoracopan

Start the discussion